NexImmune, Inc. announced that in connection with the reduction in workforce, the Company and John Trainer, the Company?s Chief Financial Officer and the Company?s Principal Financial and Accounting Officer, agreed on August 30, 2023 that Mr. Trainer?s employment with the Company will terminate effective as of September 2, 2023 (the ?Transition Date?). Effective as of the Transition Date, Mr. Trainer will transition to providing consulting and advisory services to the Company pursuant to a Consulting Agreement dated as of August 31, 2023, by and between Mr. Trainer and the Company (the ?Consulting Agreement?), which agreement may be terminated by either party upon 15 days? written notice.

The foregoing description of the Consulting Agreement is not complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which will be filed as an exhibit to the Company?s quarterly report on Form 10-Q for the quarter ending September 30, 2023. On August 30 2023, Timothy Stover, NexImmune, Inc. s Vice President, Corporate Controller, was appointed the Principal Financial and Accounting Officer of the Company effective as of September 2, 2023. Mr. Trainer previously served as the Principal Financial and Accounting Officer of the Company.

Mr. Stover joined the Company as Vice President, Corporate Controller, in June 2021. From 2018 to 2021, Mr. Stover served as Executive Director, Corporate Controller, at Autolus Therapeutics Plc., a publicly traded, clinical-stage pharmaceutical company. From 2017 to 2018, Mr. Stover served as Director, Financial Reporting for Sucampo Pharmaceuticals, Inc., and from 2014 to 2017, as Associate Director of External Reporting & Technical Accounting at Iridium Communications Inc. Prior to that, Mr. Stover worked as a Senior Manager at Ernst & Young LLP.

Mr. Stover received B.A. in Economics from Wittenberg University and an MPA from American University, and is a Certified Public Accountant in the State of Virginia.